scispace - formally typeset
D

Donato Alarcón-Segovia

Researcher at National Autonomous University of Mexico

Publications -  269
Citations -  13130

Donato Alarcón-Segovia is an academic researcher from National Autonomous University of Mexico. The author has contributed to research in topics: Lupus erythematosus & Antibody. The author has an hindex of 55, co-authored 269 publications receiving 12796 citations. Previous affiliations of Donato Alarcón-Segovia include Soroka Medical Center & Universidad Autónoma de San Luis Potosí.

Papers
More filters
Journal ArticleDOI

Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients.

TL;DR: Doctors should be cautious in prescribing high doses of corticosteroids or immunosuppressants to patients with SLE solely because they have high titers of ACLA, and it is proposed that such criteria could be applied to the definition of the antiphospholipid syndrome.
Journal ArticleDOI

Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus.

TL;DR: The results indicate that the Ig production by SLE B lymphocytes is largely IL-10 dependent, and that the increased production ofIL-10 by Sle B lymphocyte and monocytes may represent a critical mechanism in the emergence of the autoimmune manifestations of the disease.
Journal ArticleDOI

Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus

TL;DR: The study shows the involvement ofIL-10 in the pathogenesis of SLE, and indicates that the use of IL-10 antagonists may be beneficial in the management of refractory SLE.
Journal ArticleDOI

Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort.

TL;DR: American Indian-white Mestizo SLE patients and those with higher socioeconomic level were more likely to have familial autoimmunity and a polygenic additive model applies for SLE.